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Summary. We studied the relation between disease ac- 
tivity in rheumatoid arthritis (RA) and the microhetero- 
geneity of transferrin. Using crossed immuno isoelectric 
focusing, transferrin microheterogeneity patterns were 
analyzed in sera of healthy individuals, nonanemic RA 
patients, iron deficient RA patients and RA patients with 
the anemia of chronic disease (ACD). In all RA groups a 
significant shift in the microheterogeneity pattern was 
observed, reflecting increased synthesis of transferrins 
with highly branched glycan chains. Increased isease 
activity correlated with both the induction of ACD and 
the change in transferrin glycosylation, which was, there- 
fore, most pronounced in ACD. Generally, an increased 
synthesis of glycoproteins is accompanied by alterations 
in their glycosylation pattern. Since transferrin is a nega- 
tive acute phase protein, our results indicated that changes 
in synthetic rates and changes in glycosylation i duced in 
the acute phase response are regulated independently. 
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Introduction 
Rheumatoid arthritis (RA) is often accompanied by ane- 
mia which can be of different origins [1, 2]. Iron deficiency 
anemia [3, 4] and the anemia of chronic disease (ACD) [5] 
are frequently associated with active RA. Many studies 
have been carried out to elucidate the pathogenesis of
ACD in RA. Concepts that have been postulated include 
inhibitory effects of cytokines on erythropoiesis [6-8] and 
a decreased erythropoietin responsiveness [2,9]. Other 
factors, such as impaired iron release by the mononuelear 
phagocyte system (MPS) [10-12] and decreased iron 
uptake and transferrin binding by erythroblasts [13], are 
thought o contribute to the genesis of ACD by reducing 
erythroblast iron availability. 
Correspondence to: A. J. G. Swaak 
Iron fluxes between different compartments are thought 
to rely predominantly on transport by transferrin [14]. 
Transferrin iron saturation, the affinity of transferrin for 
it receptor and the number of transferrin receptors ex- 
pressed by erythroblasts determine erythroblast iron up- 
take in this scheme. 
Being a glycoprotein with N-linked glycans, transfer- 
tin is subject o the phenomenon ofmicroheterogeneity. 
This involves structural variation in the carbohydrate 
moiety of transferrin, which results in a limited number of 
transferrin isotypes that can be distinguished and quanti- 
tated electrophoretically [15]. Alterations in the relative 
proportions of the transferrin variants, reflecting changes 
in glycosylation, have been described inpregnancy and in 
several chronic diseases including RA, hemochromatosis 
and cancer [15, 16]. 
Current data on the microheterogeneity of transferrin 
suggest that functional properties of transferrin, such as 
the affinity to its receptor, can be modulated by this phe- 
nomenon [14, 17, 18]. This, in turn, may alter the biolog- 
ical activity of transferrin and could, therefore, influence 
iron delivery to target organs [14, 15, 17, 18]. 
In acute and chronic inflammatory conditions, in- 
creased synthesis of several positive acute phase glyco- 
proteins (APG's) has been shown to be accompanied by 
changes in their microheterogeneity [19-23]. It is pro- 
posed that regulation of both synthesis and glycosylation 
of APG's is mediated by tumor necrosis factor alpha 
(TNF), interleukin-1 (IL-1), interleukin-6 (IL-6) and 
transforming growth factor/~i [24-27]. 
In RA the existence of both ACD [4, 9] and alterations 
in the glycosytation pattern of a number of positive 
APG's appear to correlate with disease activity [22, 23], 
suggesting that changes in glycosylation are a direct con- 
sequence of an increase in the rate of synthesis of positive 
APG's. Transferrin is considered to be a negative acute 
phase protein [28]. Indeed, in RA patients with active RA 
and ACD transferrin levels are decreased [5, 12]. 
The aim of this study was to assess the relation be- 
tween the microheterogeneity pattern of transferrin and 
the serological disease activity in RA, since changes that 
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are postulated to alter iron transport might be operative 
in ACD in RA. 
Patients and methods 
Patients. Serum was obtained from 21 healthy volunteers (controls) 
and from 25 patients with RA fitting the revised American Rheuma- 
tism Association (ARA) criteria [29]. Written informed consent was 
obtained from all subjects. The patients were divided into three 
groups. Group 1 comprised nine nonanemic patients with a mean 
(+ SD) age of 54 + 5 years and a mean (+ SD) disease duration of 
6 _ 3 years. Group 2 comprised seven patients with iron deficiency 
anemia based on the absence of stainable bone marrow iron. The 
patients in this group had a mean (___ SD) age of 56_ 5 years and a 
mean (___ SD) disease duration of 6 + 3 years. Group 3 comprised 
nine patients with ACD based on normal to increased bone marrow 
iron. The patients in group 3 had a mean (-I- SD) of 59__+ 7 years and a0 
a mean (-t- SD) disease duration of 8 -t- 4 years. Mean age, sex and 
mean disease duration did not differ significantly between the three 
RA groups. All patients used nonsteroidal nti-inflammatory 70 
drugs, whereas 18(72%) were on long-acting antirheumatic drugs. 
Clinical disease activity was highest in group 3 and lowest in 
group 1. 6o 
Other causes of anemia were excluded byhistory-taking (present 
or past ulcer disease, other gastrointestinal disease or complaints, 
5O hypermenorrhoea and hematuria), by checking for stools negative 
for occult blood, a normal vitamin B12, folic acid, Coombs test, 
creatinine clearance and absence of microscopic hematuria. ~ g 
The protocol for this study was accepted by the Medical Ethics .~ 40 
Committee of the Dr. Daniel den Hoed Clinic. ~ 
Laboratory procedures. Erythrocyte parameters and disease activity 
were assessed as follows. Hemoglobin (Hb), hematocrit (Ht), retic- 
ulocytes, mean cell volume (MCV), serum iron, transferrin, ferritin 
and erythrocyte sedimentation rate (ESR) were measured using 
standard laboratory procedures. Iron saturation was determined by 
means of the ratio, serum iron/total iron binding capacity. C-reac- 
tive protein (CRP) was assessed by immunodiffusion techniques 
and Clq binding was measured by the method of Zubler and Lam- 
bert [30]. Bone marrow was aspirated after posterior iliac crest 
puncture and stained for iron using Perl's Prussian blue staining. 
Assessment of transferrin mieroheterogeneity. Crossed immuno iso- 
electric focusing was c rried out as described previously [15, 31]. 
Briefly, in the first phase transferrin subfractions were separated by
isoelectric focusing onpolyacrylamide g lstrips carrying an immo- 
bilized pH-gradient. The second phase, which was run perpendicu- 
larly to the first, involved a rocket immunoelectrophoresis of all 
transferrin fractions imultaneously. This re ulted in a pattern in 
which nine transferrin fractions were separated due to differences in 
sialic acid content; increased sialylation over four residues per mol- 
ecule indicated increased branching of the glycans attached to the 
protein [15]. The relative proportions were ascertained by measure- 
ment of the areas enclosed by the immunoelectrophoretic peaks, 
and relative concentrations were derived from combining these data 
with total transferrin concentration, which had been determined by 
standard turbidemetric assay. In Fig. 1, examples are shown of a 
normal microheterogeneity pattern and ofa pattern obtained from 
a RA patient with ACD. 
Data obtained were divided into three subgroups: the low sialy- 
lated transferrin fractions (LSTf; the sum of 0-, 1-, 2- and 3-sialo- 
transferrin), the 4-sialotransferrin fraction (4-STf; this is the pre- 
dominant fraction in normal serum) and the highly sialylated trans- 
ferrin fractions (HSTf; the sum of 5- to 8-sialotransferrin). This 
simplied classification was based on earlier observations that within 
these three groups, changes occuring in the relative amounts of 
transferrin fractions display similar t ends [15], allowing for this 
simplification fpresentation. All microheterogeneity patterns were 
assessed in duplicate. 
Fig. 1A, B. Transferrin microheterogeneity patterns analyzed by 
crossed immuno isoeleetric focusing. A Healthy individual; B rheuma- 
toid arthritis associated with the anemia of chronic disease. The 
indices beneath the patterns indicate the number of sialic acids 
attached to he N-linked glycans of corresponding subfractions 
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Fig. 2. Percentage distribution of the transferrin subfractions in 
controls, group 1 (RA-nonanemics), group 2 (RA-iron deficiency 
anemia) and group 3 (RA-anemia of chronic disease) 
Statistical nalysis. Normally distributed data were compared using 
Student's t-test and non-parametric data by the Mann-Whitney 
U-test. Coefficients of correlation were calculated using Spearman's 
test. 
Results 
Iron status and RA-disease activity 
Patient characteristics are shown in Table 1. In compari-  
son with group ] (nonanemic patients) transferrin was 
significantly lower in group 3 (ACD) and significantly 
elevated in group 2 (iron deficiency anemia). In all 
groups, however, transferrin was lower than in controls 
(mean 38.2 gmol/1). Total transferrin concentrat ion corre- 
lated with ESR (r=0.55, P<0.01)  and CRP ( r=-0 .48 ,  
P < 0.05) in group 1 and group 3. 
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Table 1 a, b. Patient characteristics in groups 1, 2 and 3. a Erythro- 
cyte variables and iron status, b Parameters ofdisease activity. Data 
are expressed as median with range 
Group I Group 2 Group 3 
a 
Erythrocyte parameters 
Hb (mmol/1) 8.0 6.5 6.6 
(7.4-10.9) (7.7-8.7) (4.3-7.1) (5.7-6.9) 
Ht (1/I) 0.39 0.34 0.31 
(0.36-0.51) (0.35-0.42) (0.24-0.37) (0.28 -0.35) 
MCV (fl) 88 85 87 
(80-96) (80-116) (61 95) (80-98) 
Reticulocytes (0/00) 13 11 17 
(1-39) (5-26) (1-30) 
Iron status 
Iron (gmol/l) 6 6 4 
(14-30) (1-11) (2-10) (2-17) 
Transferrin 28 32 * 23 ** 
(25-55 gmol/1) (20-39) (26-41) (18 32) 
Iron saturation 12 11 9 
(%) (2-23) (4-15) (4-27) 
Ferritin (gg/1) 50 10 ** 125 *** 
(20-150) (10-326) (10-53) (89-432) 
b 
Disease activity 
ESR (ram/l) 36 57 * 87 *** 
(<10) (21-65) (32-70) (52-105) 
CRP (mg/1) 23 20 35 ** 
(<6) (2-54) (2-78) (11-121) 
Clqba (%) 8 19 25** 
(<7) (3-32) (3-78) (5 75) 
* P<0.10; **P<0.05; ***P<0.01, data compared to the non- 
anemic group 
Table 2. Relation between percentages of transferrin subfractions 
and disease activity and hemoglobin. % LSTf= % low sialylated 
transferrin fractions; % 4-STf= % 4-sialotransferrin; % HSTf= % 
highly sialylated transferrin fractions; NS = not significant 
% LSTf % 4-STf % HSTf 
ESR r = - 0.73 r = - 0.52 r = 0.74 
(e < 0.0005) (e < 0.025) (P < 0.0005) 
CRP r = - 0.61 r = - 0.29 r = 0.49 
(P < 0.005) (N. S.) (P < 0.025) 
Clqba r= -0.87 r= -0.55 r = 0.75 
(P<O.O05) (P<O.05) (P<O.01) 
Hb r = 0.69 r = 0.50 r = - 0.69 
(P < 0.005) (P < 0.025) (P < 0.005) 
The ferritin level was significantly elevated in group 3 
and significantly decreased in group 2 compared to 
group 1. The values of the iron status in the control group 
were within the normal range. 
Disease activity, as assessed by ESR (although it is 
known that ESR and Ht correlate negatively to some 
extent), CRP and Clqba was highest in group 3, interme- 
diate in group 1 and lowest in group 1. 
Transferrin microheterogeneity 
A shift in transferrin microheterogeneity was evident in 
all RA groups (see Fig. 2). This change was characterized 
by a significant increase in the percentage of highly sialy- 
lated transferrin fractions (% HSTf) (P< 0.01) and a sig- 
nificant decrease of the percentage of 4-sialotransferrin 
(% 4-STf; P<0.01).  The percentage of low sialylated 
transferrin fractions (% LSTI) was decreased in all 
groups, but only significantly in group 3 (P< 0.01). 
Compared with group 1, the % HSTfwas significantly 
higher (P < 0.01) and the % 4-STf ws significantly lower 
in group 3 (P< 0.05). The % LSTfwas significantly lower 
in group 3 (P<0.01) compared to both groups 2 and 
group 1. These results showed that the shift to highly 
branched glycan chains exhibits the same pattern in all 
RA groups as the degree of disease activity. The shift was 
most pronounced in group 3, intermediate in group 2 and 
least pronounced in group 1. 
Table 2 shows that an increased inflammatory activity 
was associated with an increased % HSTf  and a de- 
creased % 4-STf and % LSTf. An inverse relation was 
shown between the % HSTf  and Hb, whereas the % 
4-STf and % LSTf correlated positively with Hb. 
Discussion 
The aim of this study was to assess transferrin micro- 
heterogeneity in RA and to relate this to disease activity. 
Our results showed that increasing disease activity was 
associated with preferential synthesis of transferrin vari- 
ants with highly branched glycan chains. Since the degree 
of inflammatory activity was highest in ACD, the shift in 
transferrin microheterogeneity was most pronounced in 
this group. 
It has been shown that qualitative changes in the 
glycosylation of glycoproteins can be accompanied by 
changes in their functional properties [21, 32-34]. During 
pregnancy, an increment of the highly sialylated transfer- 
tin fractions is thought o serve a functional purpose since 
it coincides with the increase in iron fluxes to both the 
placenta nd the maternal bone marrow [14, 15, 17]. Re- 
cent work demonstrated that highly sialylated transfer- 
rins have a higher affinity for the transferrin receptor 
expressed at the maternal side of the placenta (de Jong 
et al., manuscript in preparation). This receptor is identi- 
cal to the transferrin receptor isolated from reticulocytes, 
with respect o molecular size and immunoreactivity [35]. 
The high correlation between changes in transferrin mi- 
croheterogeneity and disease activity suggests that the 
changes in glycosylation are of functional significance. 
The increased synthesis of highly sialylated transferrin 
fractions in the face of both the impaired erythroblast 
iron availability in ACD and the counteractive decrease 
in total transferrin protein synthesis may, therefore, be 
viewed as part of the compensatory mechanism attempt- 
ing to facilitate iron transport o erythroblasts. In accor- 
dance with this proposal is the relation between the pref- 
erential synthesis of highly sialylated transferrins and the 
decrease in Hb. Despite this possible compensation, cry- 
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thropoiesis remains impaired; this may be related to in- 
hibitory effects of cytokines. TNF and IL-1 suppress ery- 
throid colony growth in vitro and their serum levels are 
increased in active RA [6, 36-39]. Thus, the inhibited 
erythroblast iron uptake, which has been shown to ac- 
company the diminished erythropoiesis in ACD [13] 
might be attributed to increased levels of TNF and IL-1. 
Alternatively, the decreased iron incorporation by ery- 
throblasts may be related to an impaired erythropoietin 
(EPO) responsiveness, thought o be present in ACD in 
RA [2, 9], since EPO is able to increase transferrin recep- 
tor expression by erythroblasts [40] with a concomitant 
facilitation of iron uptake. An interesting observation i  
this respect is that treatment of RA patients with ACD 
with recombinant human erythropoietin (r-Hu-EPO) is 
accompanied by an increase in serum soluble transferrin 
receptor (sTIR) levels [41]. It has been shown that sTill 
levels correlate with tissue Tilt levels and that higher sTill 
levels may reflect iron deficiency [42-44]. The increase in 
sTill levels during r-Hu-EPO therapy might, therefore, 
indicate an increased erythropoiesis accompanied by a 
decrease in body iron stores based on increased iron mo- 
bilization and iron utilization [41]. Assuming a role for 
transferrin microheterogeneity in the fine-tuning of iron 
fluxes, it might be speculated that alterations in the glyco- 
sylation pattern of transferrin are associated with changes 
in sTill levels. 
The fact that transferrin is a negative acute phase 
protein facilitates a second conclusion from the observed 
shift in microheterogeneity. One of the main characteris- 
tics of the acute phase response is the change in the rates 
of synthesis of plasma glycoproteins [28]. In addition, 
concomitant alterations are induced in the glycosylation 
of various positive acute phase glycoproteins (APGs) 
[19-21]. In RA for instance, the changes in the carbo- 
hydrate moieties of alpha-l-acid glycoprotein and hap- 
toglobin, both positive APGs, are related to the degree of 
inflammatory activity [22, 23]. It has been shown for nu- 
merous glycoproteins, including transferrin, that changes 
in the carbohydrate moiety are a concomitant feature of 
increased synthesis, and a linkage between the regulation 
of gene expression and glycosylation, has been suggested 
[14, 19]. Our study showed that in active RA posttransla- 
tional modification is directed towards increased synthe- 
sis of transferrin carrying highly branched glycans, under 
conditions where translation of the gene has diminished. 
This indicated that in the acute phase response, although 
an altered clearance of the various transferrin isotypes 
cannot be excluded, these processes are regulated by dif- 
ferent mechanisms. This is supported by the observed 
dissociation between the mechanisms that regulate the 
synthesis of alpha-fetoprotein a d el protease inhibitor 
and their glycosylation [24, 45]. 
In the acute phase response, changes in both rate of 
synthesis and carbohydrate moieties of positive APG's 
are thought o be mediated by cytokines [24-27]. Both 
TNF and IL-6 exert a negative influence on transferrin 
synthesis in vitro [26, 46], whereas it is not known 
whether these cytokines affect he glycosylation of trans- 
ferrin. Transferrin levels in the three RA groups were 
lower than in controls and the inverse relation between 
transferrin and parameters of disease activity confirmed 
the fact that transferrin is a negative APG. In active RA, 
TNF and IL-6 levels are elevated and correlate with dis- 
ease activity [8, 39, 47]. This suggests that TNF and IL-6 
might inhibit the synthesis of transferrin i  active RA and 
possibly influence its glycosylation pattern. 
In conclusion, our study showed that in RA the induc- 
tion of both ACD and the shift in transferrin microhetero- 
geneity was related to increased isease activity. As a 
response to counter-reproductive effects, such as the 
impaired erythroblast iron uptake and the decrease in 
transferrin concentration, preferential synthesis of highly 
sialylated transferrin variants in ACD may serve as a 
compensatory mechanism to improve erythroblast iron 
availability. 
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